NCRN CLL207 study of alemtuzumab consolidation in chronic lymphocytic leukaemia: final response assessment and early follow-up (on behalf of the NCRI CLL Trials Sub-Group)

被引：0
|
作者：
Varghese, A. M. [1 ]
Cohen, D. [2 ]
Pocock, C. F. E. [3 ]
Rawstron, A. [4 ]
Gregory, W. M. [2 ]
Smith, A. [2 ]
Skinner, E. [2 ]
Critchley, A. [1 ]
Milligan, D. [5 ]
Dearden, C. E. [6 ]
McCarthy, H. [7 ]
Fegan, C. [8 ]
Follows, G. A. [9 ]
Hillmen, P. [1 ]
机构：
[1] St James Univ Hosp, Dept Haematol, Leeds LS9 7TF, W Yorkshire, England
[2] Univ Leeds, Clin Trials Res Unit, Leeds LS2 9JT, W Yorkshire, England
[3] E Kent Hosp NHS Trust, Dept Haematol, Canterbury, Kent, England
[4] Leeds Teaching Hosp NHS Trust, HMDS, Leeds, W Yorkshire, England
[5] Birmingham Heartlands Hosp, Birmingham, W Midlands, England
[6] Royal Marsden Hosp, Dept Haematol, London SW3 6JJ, England
[7] Royal Bournemouth Hosp, Dept Haematol, Bournemouth, Dorset, England
[8] Cardiff & Vale NHS Trust, Dept Haematol, Cardiff, S Glam, Wales
[9] Addenbrookes Hosp, Dept Haematol, Cambridge CB2 2QQ, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2011年 / 153卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
16
引用
收藏
页码：8 / 8
页数：1
相关论文
共 23 条
  • [1] NCRN CLL207 Study of Alemtuzumab Consolidation In CLL: Final Response Assessment and Early Follow-up (on Behalf of the NCRI CLL Trials Sub-Group)
    Varghese, Abraham M.
    Cohen, Dena
    Pocock, Christopher F. E.
    Rawstron, Andy
    Gregory, Walter M.
    Smith, Alex
    Skinner, Emma
    Critchley, Anne
    Milligan, Donald
    Dearden, Claire E.
    McCarthy, Helen
    Fegan, Chris
    Follows, George A.
    Hillmen, Peter
    BLOOD, 2010, 116 (21) : 33 - 34
  • [2] NCRN CLL207 STUDY OF ALEMTUZUMAB CONSOLIDATION IN CHRONIC LYMPHOCYTIC LEUKAEMIA: REPORT OF THE PLANNED INTERIM ANALYSIS
    Hillmen, P.
    Cohen, D. R.
    Dearden, C.
    Follows, G.
    Gregory, W. M.
    Smith, A. F.
    Skinner, E. J.
    Critchley, A.
    Rawstron, A. C.
    Fegan, C. D.
    McCarthy, H.
    Pocock, C. F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 144 - 144
  • [3] Final report of the UKCLL02 trial: A phase II study of subcutaneous alemtuzumab plus fludarabine in patients with fludarabine refractory CLL (on behalf of the NCRI CLL trials sub-group).
    Sayala, Hazem A.
    Moreton, Paul
    Jones, Richard A.
    Rawstron, Andy C.
    O'Connor, Sheila J.
    Evans, Paul
    Anthony, Carter
    Dearden, Claire
    Matutes, Estella
    Pettitt, Andrew R.
    Kennedy, Daniel B.
    Hillmen, Peter
    BLOOD, 2006, 108 (11) : 14A - 15A
  • [4] Report of the UKCLL02 trial: a phase II study of subcutaneous alemtuzumab and fluclarabine in patients with fluclarabine refractory CLL (on behalf of the NCRI CLL trials sub-group)
    Sayala, H. A.
    Moreton, P.
    Jones, R. A.
    Rawstron, A. C.
    O'Connor, S. J.
    Evans, P. E.
    Carter, A.
    Dearden, C.
    Matutes, E.
    Pettitt, A. R.
    Kennedy, B. D.
    Hillmen, P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 137 : 3 - 3
  • [5] Interim report of the UKCLL02 trial: A phase II study of subcutaneous alemtuzumab plus fludarabine in patients with fludarabine refractory CLL (on behalf of the NCRI CLL trials sub-group).
    Sayala, H
    Moreton, P
    Richard, JA
    Andy, RC
    Sheila, O
    Paul, E
    Anthony, C
    Claire, D
    Estella, M
    Andrew, PR
    Daniel, KB
    Peter, H
    BLOOD, 2005, 106 (11) : 599A - 600A
  • [6] Interim report of the UKCLL02 Trial: a phase II study of subcutaneous alemtuzumab plus fludarabine in patients with fludarabine refractory CLL (on behalf of the NCRI CLL Trials Sub-Group)
    Sayala, HA
    Moreton, P
    Jones, RA
    Rawstron, AC
    O'Connor, SJ
    Evans, P
    Carter, A
    Dearden, C
    Matutes, E
    Pettitt, AR
    Kennedy, DB
    Hillmen, P
    BRITISH JOURNAL OF HAEMATOLOGY, 2006, 133 : 3 - 3
  • [7] Long Term Survival Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab In Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group)
    Varghese, Abraham M.
    Sayala, Hazem A.
    Moreton, Paul
    Jones, Richard A.
    Rawstron, Andy
    O'Connor, Sheila J.
    Evans, Paul
    Anthony, Carter
    Dearden, Claire E.
    Matutes, Estella
    Pettitt, Andrew R.
    Kennedy, Daniel B.
    Barrans, Sharon
    Worrillow, Lisa
    Hillmen, Peter
    BLOOD, 2010, 116 (21) : 407 - 408
  • [8] Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation
    Varghese, Abraham M.
    Howard, Dena R.
    Pocock, Christopher
    Rawstron, Andy C.
    Follows, George
    McCarthy, Helen
    Dearden, Claire
    Fegan, Christopher
    Milligan, Donald
    Smith, Alexandra F.
    Gregory, Walter
    Hillmen, Peter
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 176 (04) : 573 - 582
  • [9] Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission - long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG)
    Schweighofer, Carmen D.
    Ritgen, Matthias
    Eichhorst, Barbara F.
    Busch, Raymonde
    Abenhardt, Wolfgang
    Kneba, Michael
    Hallek, Michael
    Wendtner, Clemens-Martin
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 144 (01) : 95 - 98
  • [10] An open-label phase II study to investigate the safety and efficacy of rituximab plus chlorambucil in previously untreated patients with CD20-positive B-cell chronic lymphocytic leukaemia (CLL): On behalf of the NCRI CLL sub-group
    Hillmen, P.
    Gribben, J. G.
    Follows, G. A.
    Milligan, D. W.
    Sayala, H. A.
    Moreton, P.
    Oscier, D.
    Dearden, C. E.
    Kennedy, D. B.
    Pettitt, A. R.
    Nathwani, A.
    Cohen, D.
    Gregory, W. M.
    Rawstron, A. C.
    Hayward, C. R. W.
    Pocock, C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 149 : 2 - 2
123